ArticleFish physiology and biochemistry2025
Muscle biochemistry and residue accretion in male Oreochromis niloticus fries administered therapeutic, subtherapeutic and overdoses of dietary oxytetracycline.
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oxytetracycline (OTC), an approved antibiotic for aquaculture, is under strict control and regulatory endeavour. This study compared the effects of oral administration of graded doses of OTC comprising the therapeutic (80 mg/kg biomass/day), subtherapeutic (40 mg) and overdoses (240, 400 and 800 mg) in male Nile tilapia Oreochromis niloticus fries (0.64 ± 0.02 g) when fed for 10 consecutive days and observed for 22 days post-OTC-dosing (POD) period. A dose-dependent reduction in food intake, survival and muscle calcium, chloride, malondialdehyde and superoxide dismutase was observed, while the muscle glucose significantly increased. However, the changes were reversible with dose cessation. The fries of the therapeutic dose group recorded the maximum biomass, while the overdosed groups recorded a significant decline in weight gain. On day 10 of dosing, all groups' muscle OTC residues peaked. The residues in the subtherapeutic and therapeutic dose groups were lowered below the maximum residue limit (MRL) of 100 ng/g on day 10 POD. The residues were further reduced close to the MRL in the overdosed groups on day 22 POD. The fries tolerated the therapeutic dose well and showed effective adaptive responses. Considering muscle residue accretion and physiological responses, OTC can be endorsed as a safe drug for in-feed administration to tilapia fries. However, the sensible use of this approved drug is essential for sustainable aquaculture.
Indexed as
Identifiers
39827248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.